Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
April 24, 2024 08:00 ET | Bionano Genomics
Researchers used Cas9-directed Nanopore sequencing to validate structural variants detected by optical genome mapping in leukemia samples.
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
April 11, 2024 08:00 ET | Bionano Genomics
Researchers used optical genome mapping in addition to whole genome sequencing in pediatric leukemia samples and identified additional structural variants.
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 28, 2024 15:30 ET | Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
2024 KOL Interview on Acute Myeloid Leukemia (AML) Treatment in Southern US: Expert Insights and Emerging Therapies - Magrolimab, Quizartinib, Crenolanib, Gilteritinib, and Uproleselan
March 21, 2024 05:49 ET | Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) KOL Interview - US, South" report has been added to's offering. This report presents an...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024 16:05 ET | Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Kura Oncology Logo
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 16:01 ET | Kura Oncology, Inc.
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008...
NMDP BioTherapies
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
January 30, 2024 09:00 ET | NMDP
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president.
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
January 22, 2024 21:23 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to's offering. The latest comprehensive research on...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024 16:01 ET | Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...